Literature DB >> 7026327

Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics.

S Madsbad, T Krarup, L Reguer, O K Faber, C Binder.   

Abstract

In 14 insulin dependent diabetics past their initial remission period B-cell function was evaluated using a test meal before and after 1 week of strict blood glucose control, and again 3 weeks later when the patients were outpatients on conventional therapy. Eight patients with fasting C-peptide above 0.07 nmol/l improved their B-cell function significantly (p Less Than 0.05) during the period of strict blood glucose control. However, the improvement was of short duration and was absent 3 weeks later in most patients. Six patients with fasting C-peptide below or equal to 0.07 nmol/l had no significant improvement in B-cell function during the period of strict control. The study shows that B-cell function and degree of blood glucose control are related in patients with fasting C-peptide above 0.07 nmol/l, and that B-cell function can change within days.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7026327     DOI: 10.1007/bf00252760

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  19 in total

1.  Glucose-stimulated insulin secretion during "remission" of juvenile diabetes.

Authors:  B Weber
Journal:  Diabetologia       Date:  1972-07       Impact factor: 10.122

2.  Radioimmunological determination of human C-peptide in serum.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1975-12       Impact factor: 10.122

3.  Beta-cell function improved by supplementing basal insulin secretion in mild diabetes.

Authors:  R C Turner; S T McCarthy; R R Holman; E Harris
Journal:  Br Med J       Date:  1976-05-22

4.  beta-cell function in children with diabetes.

Authors:  J Ludvigsson; L G Heding
Journal:  Diabetes       Date:  1978       Impact factor: 9.461

5.  Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump.

Authors:  W V Tamborlane; R S Sherwin; M Genel; P Felig
Journal:  N Engl J Med       Date:  1979-03-15       Impact factor: 91.245

6.  Sustained insulin-induced remissions of juvenile diabetes by means of an external artificial pancreas.

Authors:  J Mirouze; J L Selam; T C Pham; E Mendoza; A Orsetti
Journal:  Diabetologia       Date:  1978-04       Impact factor: 10.122

7.  C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control.

Authors:  J Ludvigsson; L G Heding; Y Larsson; E Leander
Journal:  Acta Paediatr Scand       Date:  1977-03

8.  Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-etide response to intravenous glucagon.

Authors:  C Hendriksen; O K Faber; J Drejer; C Binder
Journal:  Diabetologia       Date:  1977-12       Impact factor: 10.122

9.  Continuous subcutaneous insulin infusion: improved blood-glucose and intermediary-metabolite control in diabetics.

Authors:  J C Pickup; H Keen; J A Parsons; K G Alberti; A S Rowe
Journal:  Lancet       Date:  1979-06-16       Impact factor: 79.321

10.  Characterization of seven C-peptide antisera.

Authors:  O K Faber; C Binder; J Markussen; L G Heding; V K Naithani; H Kuzuya; P Blix; D L Horwitz; A H Rubenstein
Journal:  Diabetes       Date:  1978       Impact factor: 9.461

View more
  14 in total

Review 1.  Beta cell mass in diabetes: a realistic therapeutic target?

Authors:  J J Meier
Journal:  Diabetologia       Date:  2008-03-04       Impact factor: 10.122

2.  Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?

Authors:  J J Meier; A Bhushan; A E Butler; R A Rizza; P C Butler
Journal:  Diabetologia       Date:  2005-10-05       Impact factor: 10.122

3.  Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: the FUSIDM trial.

Authors:  I Conget; E Aguilera; S Pellitero; S Näf; K Bendtzen; R Casamitjana; R Gomis; F Nicoletti
Journal:  Diabetologia       Date:  2005-07-02       Impact factor: 10.122

4.  Prevalence of residual B cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetes.

Authors:  S Madsbad
Journal:  Diabetologia       Date:  1983-03       Impact factor: 10.122

5.  Glycaemic control and suppressor cell activity in patients with insulin-dependent diabetes mellitus.

Authors:  K Buschard; S Madsbad; T Krarup; J Rygaard
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

6.  The transient effect of strict glycaemic control on B cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients.

Authors:  S Madsbad; T Krarup; O K Faber; C Binder; L Regeur
Journal:  Diabetologia       Date:  1982-01       Impact factor: 10.122

7.  Clinical application of the 24-H urinary C-peptide excretion rate and its relationship to metabolic control in diabetics.

Authors:  R Pasquali; P Biso; G Baraldi; L Mattioli; M Capelli; F Pasqui; N Melchionda
Journal:  Acta Diabetol Lat       Date:  1983 Apr-Jun

8.  Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients.

Authors:  P Vague; R Picq; M Bernal; V Lassmann-Vague; B Vialettes
Journal:  Diabetologia       Date:  1989-05       Impact factor: 10.122

9.  Beta-cell function recovery is not the only factor responsible for remission in type I diabetics: evaluation of C-peptide secretion in diabetic children after first metabolic recompensation and at partial remission phase.

Authors:  E Schober; G Schernthaner; H Frisch; M Fink
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256

10.  Residual C-peptide in patients with Type 1 diabetes and multiethnic backgrounds.

Authors:  Mirella Hansen de Almeida; Joana Rodrigues Dantas; Bianca Barone; Fabiano Marcel Serfaty; Rosane Kupfer; Marta Albernaz; Maria Rocio Bencke; Lenita Zajdenverg; Melanie Rodacki; José Egídio Paulo de Oliveira
Journal:  Clinics (Sao Paulo)       Date:  2013-01       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.